Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells

European Journal of Haematology

Volumn 94, Issue 1, 2015, Pages 74-78

  Austin, Gemma ^a   Holcroft, Alison ^a   Rinne, Natasha ^a   Wang, Lihui ^a   Clark, Richard E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; HOCT1; Imatinib; Pregnane X receptor; Retinoid acid receptor; Retinoid X receptor

Indexed keywords

ALITRETINOIN; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; HUMAN ORGANIC CATION TRANSPORTER 1; IMATINIB; LIVER X RECEPTOR ALPHA; MINERALOCORTICOID RECEPTOR; ORGANIC CATION TRANSPORTER 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; RETINOIC ACID; RETINOID ACID RECEPTOR; RETINOID X RECEPTOR; RIFAMPICIN; UNCLASSIFIED DRUG; VITAMIN RECEPTOR; STEROID RECEPTOR;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MYELOID LEUKEMIA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; UPREGULATION; AGONISTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; ORGANIC CATION TRANSPORTER 1; RECEPTORS, STEROID; RETINOID X RECEPTORS; TRANSCRIPTION, GENETIC;

EID: 84922867413     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12409     Document Type: Article

References (19)

1. Francis S, Lucas CM, Wang L, et al. A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. Leuk Res 2013;37:752-8.
2. Daghistani M, Marin D, Khorashad JS, et al. EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood 2010;116:6014-7.
3. Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83:258-64.
4. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064-72.
5. Zhang Z, Burch P, Cooney A, et al. Genomic analysis of the nuclear receptor family: new insights into structure, regulation, and evolution from the rat genome. Genome Res 2004;14:580-90.
6. Wang L, Giannoudis A, Austin G, et al. Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. Exp Hematol 2012;40:811-9.
7. Thomas J, Wang L, Clark R, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-45.
8. Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 2003;133:2444S-7S.
9. Maeda T, Oyabu M, Yotsumoto T, et al. Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats. Drug Metab Dispos 2007;35:1580-6.
10. Köhle C, Bock KW. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 2009;77:689-99.
11. Cho SK, Yoon JS, Lee MG, et al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 2011;89:416-21.
12. Lemaire G, Benod C, Nahoum V, et al. Discovery of a highly active ligand of human pregnane x receptor: a case study from pharmacophore modeling and virtual screening to "in vivo" biological activity. Mol Pharmacol 2007;723:572-81.
13. Pérez E, Bourguet W, Gronemeyer H, et al. Modulation of RXR function through ligand design. Biochim Biophys Acta 2012;1821:57-69.
14. Le Vee M, Jouan E, Stieger B, et al. Differential regulation of drug transporter expression by all-trans retinoic acid in hepatoma HepaRG cells and human hepatocytes. Eur J Pharm Sci 2013;48:767-74.
15. Gocek E, Marchwicka A, Baurska H, et al. Opposite regulation of vitamin D receptor by ATRA in AML cells susceptible and resistant to vitamin D-induced differentiation. J Steroid Biochem Mol Biol 2012;132:220-6.
16. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-94.
17. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinibmesylate in leukemia cell line models. Blood 2003;101:2368-73.
18. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinibmesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102-6.
19. Chen Y, Tang Y, Wang MT, et al. Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res 2007;67:10361-7.